Drug Profile
MVT 1075
Alternative Names: 177Lu Human Monoclonal Antibody 5B1; 177Lu- CHX-A″-DTPA-HuMAb-5B1; 177Lu-DTPA-HuMab-5B; 90Y- CHX-A″-DTPA-HuMAb-5B1; HuMab 5B1 radioimmunotherapy agent - MabVax; HuMab-5B1 conjugated Actinium225-radioimmunotherapy agent; MVT 1916; MVT-1075; radiolabeled HuMab 5B1 antibody - MabVaxLatest Information Update: 05 May 2023
Price :
$50
*
At a glance
- Originator MabVax Therapeutics
- Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Colorectal cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 05 May 2023 CTP push 700276997: KDM updated, phase termination HE added, NDR retained as such as no development has been reported since 5 years
- 28 Apr 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)